Haoxi Health Technology Closes Private Placement

TL;DR

Haoxi Health closed its private placement, raising capital.

AI Summary

Haoxi Health Technology Limited announced the closing of a private placement on October 24, 2025. This follows a previous disclosure of the private placement on October 17, 2025. The company is a foreign private issuer based in Beijing, China.

Why It Matters

The closing of a private placement indicates the company has successfully raised capital, which could be used for growth initiatives or operational needs.

Risk Assessment

Risk Level: low — This filing is a routine update on a previously disclosed event (private placement closing) and does not introduce new significant risks.

Key Players & Entities

• Haoxi Health Technology Limited (company) — Filer of the report
• October 24, 2025 (date) — Date of the closing of the private placement
• October 17, 2025 (date) — Date of previous disclosure of the private placement

FAQ

Key Financial Figures

• $0.0025 — rdinary share of the Company, par value $0.0025 per share (the “ Shares ”),
• $0.23 — Shares ”), at a purchase price of $0.23 per Share (the “ Offering ”
• $1.2 m — hares in exchange for gross proceeds of $1.2 million, before the deduction of customar
• $0 — dinary shares, each with a par value of $0.0025, issued and outstanding as of the

Filing Documents

• ea0262030-6k_haoxi.htm (6-K) — 11KB
• 0001213900-25-102164.txt ( ) — 12KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-41933 Haoxi Health Technology Limited Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District Beijing, China +86-10-13311587976 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Closing of Private Placement As previously disclosed on a Current Report on Form 6-K filed by Haoxi Health Technology Limited (the “ Company ”) with the U.S. Securities and Exchange Commission on October 17, 2025, the Company entered into a certain securities purchase agreement (the “ SPA ”) with certain “non-U.S. Persons” (the “ Purchasers ”) as defined in Regulation S of the Securities Act of 1933, as amended (the “ Securities Act ”) on October 13, 2025. Pursuant to the SPA, the Company agreed to sell an aggregate of 5,217,391 Class A ordinary share of the Company, par value $0.0025 per share (the “ Shares ”), at a purchase price of $0.23 per Share (the “ Offering ”). The net proceeds to the Company from such Offering shall be used by the Company for working capital and general corporate purposes. The closing of the Offering and sale of the Shares occurred on October 22, 2025, when all the closing conditions of the SPA have been satisfied. The Company issued the Shares in exchange for gross proceeds of $1.2 million, before the deduction of customary expenses. The Shares were issued in reliance on the exemption from registration provided by Regulation S under the Securities Act of 1933. Following the closing of the Offering, the Company has an aggregate of 7,503,028 Class A ordinary shares, and 690,800 Class B ordinary shares, each with a par value of $0.0025, issued and outstanding as of the date of this report. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Haoxi Health Technology Limited By: /s/ Zhen Fan Name: Zhen Fan Title: Chief Executive Officer Date: October 24, 2025 2

View Full Filing

View this 6-K filing on SEC EDGAR